Requests that the FDA require the immediate revision of all SSRI and SNRI antidepressant product labels (included branded and generic formulations) to warn of serious and severe risks | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-P-1305

Requests that the FDA require the immediate revision of all SSRI and SNRI antidepressant product labels (included branded and generic formulations) to warn of serious and severe risks

Documents

Comments

273

Description

Open

Key Dates

Comment Period OpensMay 19, 2025

Documents

Type	Title	Posted	Comments	Status
Other	SSRI listening session minutes_3-24-26	Apr 24, 2026	--

Comment Statistics

Total Comments

273

Keywords

CDER

Citizen Petition

Antidepressant Coalition for Education

Requests that the FDA require the immediate

revision of all SSRI and SNRI antidepressant

product labels (included branded and generic

formulations) to warn of serious

and severe risks

Data from Regulations.gov